9MH MedX Health Corp.

MedX Receives Corporate Citizenship Award from the Melanoma Network of Canada

MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it received a Corporate Citizenship Award from the Melanoma Network of Canada (“MNC”) for MedX’s work in raising melanoma awareness.

Alexa Cain, Executive Director of MNC, and Don Fernald, a Director on MNC’s Board, presented a plaque and a glass sculpture, designed by acclaimed Canadian artist Paull Rodrigue, to the MedX team at MedX’s offices in Mississauga.

“The support from MedX has been truly amazing and inspiring. MedX has helped champion the work we do at MNC, and is our partner in providing information about early skin cancer detection, providing skin screening at our charity events,” Ms. Cain said.

Accepting the award on behalf of MedX, President and CEO Rob von der Porten said, “It is an honor for MedX to be acknowledged by the MNC. We believe in the great work they do in helping individuals and their families afflicted by melanoma and other skin cancers. We also believe that MedX’s pain-free SIAscopy technology is a game-changer for the early detection of skin cancers. Our goal is to significantly cut skin cancer mortality rates globally.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

About Melanoma Network of Canada

The Melanoma Network of Canada (MNC) provides support services, information and programs for individuals whose lives have been changed by melanoma. MNC provides the leading national voice for melanoma patients in Canada for early detection and improved treatment access and works diligently to prevent more Canadians from developing melanoma through public awareness and youth and adult education on sun safety. For more information, please visit www.melanomanetwork.ca. Charitable Registration number: 854913050RR0001

EN
13/02/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedX Health Corp.

 PRESS RELEASE

MedX to Present at Benzinga Healthcare Conference on September 30th

Mississauga, Ontario--(Newsfile Corp. - September 29, 2021) - (TSXV: MDX) ("MedX" or the "Company"), a global leader in teledermatology, is pleased to announce its participation in the Benzinga Healthcare Small Cap Conference (the "Conference"), taking place virtually on Thursday, September 30th at 4:40 PM ET. MedX President & CEO, Sylvain Desjeans, along with Mike Druhan, President Dermatological Services, will present the Company's vision for scaling access to its unique dermatological image capture technology and fully integrated telemedicine platform, DermSecure®. The screening platform ...

 PRESS RELEASE

MedX Health Corp.’s SIAscopy Technology Being Introduced to the Span...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX”) (TSX-V: MDX) announced that it has shipped an initial order in excess of $120,000 of its SIAscopy technology to Spain through its marketing partnership with OncoTech LLC. “Completing this large order early in the second quarter reinforces the growing interest in our technology as a pain-free non-invasive skin assessment tool,” noted Rob von der Porten, MedX's CEO. “OncoTech sees this as a first step in gaining awareness followed by further market penetration i...

 PRESS RELEASE

MedX Health Corp. Announces 2017 Year End Results and Granting of Shar...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2017, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $1,093,239 for the year ended December 31, 2017, an increase of 34% from revenue of $817,055 for the year ended December 31, 2016. Sales from the Company's therapeutic laser line grew by $341,488 during 2017, while revenue from SIAscopy, the Company’s skin assessment technology, was $65,304...

 PRESS RELEASE

MedX Health Corp. Adds Experienced Medical Device Professional, Scott ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Scott Spearn, an experienced medical device executive, joined the MedX team as President. Mr. Spearn has successfully built sales and distribution channels for medical devices across Canada, the United States and Latin America. His focus will be on developing and expanding MedX’s North American and international sales. Mr. Spearn will report to Robert von der Porten, CEO. “With the completion of successful financings and the f...

 PRESS RELEASE

MedX Health Corp. Announces Investor Relations Agreement

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX). The Company announces that it has received notice from the TSX-V accepting an Investor Relations Agreement entered into with Mi3 Communications Financières Inc. (the “Consultant”) with an effective date of December 1, 2017. Under the terms of the Agreement, the Consultant will carry out activities to develop the Eastern Canada shareholder base of the Company, and the Company will pay to the Consultant a monthly consideration of $5,000, tog...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch